Candida albicans Target of Rapamycin in oxidative stress responses
- Institution
- BOSTON CHILDREN'S HOSPITAL, MA
- Principal investigator
- Julia R Koehler
- Funding
- $259K
- Duration
- 2024–2026
Moonbase score
Still being scored
Abstract
Abstract The goal of this proposal is to examine the role of Candida albicans Tor1 kinase and specifically, its least- conserved domain, N-terminal HEAT repeats, in enabling this fungal pathogen to withstand oxidative stress imposed by the host immune system. We showed that C. albicans cells lacking Tor1 N-terminal HEAT repeats, which are protein-protein interaction domains, are exquisitely hypersensitive to oxidative stress. They also dysregulate dedicated oxidative stress management systems of the fungus, and their metabolic output of intermediates required in redox homeostasis is defective. Tor1 point mutants that we recently engineered, show that these severe defects are not attributable to simple hypo- or hyperactivity of the kinase. Instead, these cells’ oxidative stress management defects appear to relate to functions residing in the N-terminal HEAT repeats. Notably, we found a core enzyme of C. albicans redox homeostasis, that is structurally and functionally completely different than its human counterpart, to be dysregulated in cells lacking Tor1 N-terminal HEAT repeats. We also found that depletion of this enzyme leads to starkly decreased TORC1 signaling even in conditions of ample nutrients and absent stress. We propose to define the interactions between Tor1 and its N-terminal HEAT repeats with dedicated C. albicans oxidative stress management systems.
LOADING MOONBASE SCORE
Questions for BOSTON CHILDREN'S HOSPITAL
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · Boston Children'S HospitalNot yet scored
C. albicans cell wall stress responses and TOR signaling
Julia R Koehler · $490K · 2025–2027
- NIH · Boston Children'S Hospital67
A 90 day, Phase 3, Open Labeled Exploratory Study of RELiZORB to Evaluate Safety, Tolerability, and Nutrient Absorption in Children with Short Bowel Syndrome who are Dependent on Parenteral Nutrition
Mark Puder · $365K · 2021–2028
- NIH · Boston Children'S Hospital64
Motion and Distortion Robust Diffusion Weighted Imaging Sequences for Pediatric Patients
Onur Afacan · $398K · 2022–2027